SYRS

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SYRS

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/14	20:30	Business Wire	Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/05/14	19:42	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/05/07	22:00	Business Wire	Syros to Participate in Upcoming Investor Conferences	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/05/07	20:00	Business Wire	Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/04/09	20:00	Business Wire	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/04/03	05:30	Business Wire	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/03/27	20:30	Business Wire	Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/03/27	19:57	IH Market News	U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/03/25	20:00	Business Wire	Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/03/20	20:00	Business Wire	Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/02/27	21:00	Business Wire	Syros to Participate in TD Cowen 44th Annual Health Care Conference	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/02/15	10:56	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/02/14	10:22	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/02/14	09:02	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/02/14	08:59	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/01/08	21:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/01/08	21:00	Business Wire	Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2024/01/03	06:15	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/27	07:19	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/20	06:59	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/20	06:53	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/19	21:27	Business Wire	Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/15	06:24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/13	06:12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/09	06:23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/07	06:00	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/06	21:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/06	21:00	Business Wire	Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/12/06	07:28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SYRS	Syros Pharmaceuticals Inc
2023/11/21	21:30	Business Wire	Syros to Participate in Upcoming Investor Conferences	NASDAQ:SYRS	Syros Pharmaceuticals Inc